# Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex

> **NCT07756138** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Stanford University** · enrollment: 10 (estimated)

## Conditions studied

- Epidermolysis Bullosa Simplex

## Interventions

- **DRUG:** Filsuvez

## Key facts

- **NCT ID:** NCT07756138
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-07-02
- **Final completion:** 2028-06-18
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07756138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07756138, "Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07756138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*